Inhibition of constriction-induced reactive hyperemic edema.
D000522:Alphaprodine / Q000627:therapeutic use; D000818:Animals; D001285:Atropine / Q000627:therapeutic use; D003250:Constriction; D004487:Edema / Q000517:prevention & control*; D004837:Epinephrine / Q000627:therapeutic use; D006584:Hexamethonium Compounds / Q000627:therapeutic use; D006614:Hindlimb / Q000098:blood supply; D006940:Hyperemia / Q000517:prevention & control*; D007545:Isoproterenol / Q000627:therapeutic use; D008297:Male; D008614:Meperidine / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use; D009020:Morphine / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D010640:Phenothiazines / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010656:Phenylephrine / Q000627:therapeutic use; D051381:Rats; D013015:Sotalol / Q000627:therapeutic use; D014309:Tripelennamine / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D006584:Hexamethonium Compounds; D010640:Phenothiazines; D014662:Vasoconstrictor Agents; D000522:Alphaprodine; D010656:Phenylephrine; D014309:Tripelennamine; D009020:Morphine; D001285:Atropine; D008614:Meperidine; D013015:Sotalol; D007545:Isoproterenol; D009638:Norepinephrine; D008784:Methysergide; D004837:Epinephrine; D010646:Phentolamine